SCHEMBL557825

SCHEMBL557825

Nc1nc(Br)cnc1NCCc1ccccc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APP P05067 5/20 0.51
NUDT1 P36639 1/20 0.48
SLC29A1 Q99808 1/20 0.48
EGFR P00533 1/20 0.46
LMNA P02545 1/20 0.46
MAPK1 P28482 1/20 0.46
HTT P42858 1/20 0.46
PDE5A O76074 1/20 0.43
KMT2A Q03164 2/20 0.43
TMIGD3 P0DMS9 1/20 0.43
ADORA2A P29274 1/20 0.43
ADORA2B P29275 1/20 0.43
ADORA1 P30542 1/20 0.43
PLAU P00749 1/20 0.43
BCHE P06276 1/20 0.43
ACHE P22303 1/20 0.43
HDAC3 O15379 1/20 0.43
HDAC1 Q13547 1/20 0.43
HDAC2 Q92769 1/20 0.43
HDAC6 Q9UBN7 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3952920 0.91 HPGD (0.49) APPLMNATMIGD3ADORA2AADORA2B
SCHEMBL557824 0.88 APP (0.51) APPNUDT1SLC29A1EGFRLMNA
SCHEMBL23461169 0.86 APP (0.47) APPNUDT1SLC29A1EGFRLMNA
SCHEMBL29904352 0.86 APP (0.47) APPNUDT1SLC29A1EGFRLMNA
SCHEMBL3956502 0.79 HPGD (0.49) APPLMNATMIGD3ADORA2AADORA2B
SCHEMBL3953540 0.78 APP (0.53) APPNUDT1SLC29A1EGFRLMNA
SCHEMBL3953432 0.77 NPC1 (0.50) APPNUDT1TMIGD3ADORA2AADORA2B
SCHEMBL21223771 0.74 APP (0.52) APPNUDT1SLC29A1EGFRLMNA
SCHEMBL18627615 0.72 LDHA (0.54) APPEGFRLMNAHTT
SCHEMBL6209927 0.72 APP (0.57) APPSLC29A1EGFRLMNAMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9062008-B2 Compounds useful as inhibitors of ATR kinase VERTEX PHARMACEUTICALS INCORPORATED (US) 2015-06-23 US disclosed
US-20120035408-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-02-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120035408-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE ATR, CHEK1, MAP3K5 APP 2113/4885NUDT1 2026/4885SLC29A1 4315/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.